Related Experiment Videos
The proteins of varicella-zoster-virus
Abstract:
[35S] methionine-labelled Varicella-Zoster-Virus (VZV) was partly purified by sucrose density gradient centrifugation. Enveloped virus, checked by electron microscopy, was analyzed by high resolution polyacrylamide gel electrophoresis. A polypeptide pattern of at least 31 proteins could be identified on the fluorogram. The molecular weight of the proteins, estimated by co-electrophoresis with marker proteins, ranged from 18,000 to 240,000 daltons. Immunoprecipitation using a specific human antiserum showed at least 14 proteins.
Insights
Researchers analyzed Varicella-Zoster-Virus (VZV) proteins using advanced electrophoresis. They identified at least 31 VZV proteins, with molecular weights ranging from 18,000 to 240,000 daltons.
Area of Science:
- Virology
- Molecular Biology
- Biochemistry
Background:
- Varicella-Zoster-Virus (VZV) is a significant human pathogen.
- Understanding the VZV proteome is crucial for developing antiviral strategies.
Purpose of the Study:
- To characterize the polypeptide composition of purified Varicella-Zoster-Virus.
- To determine the molecular weights and identify VZV-encoded proteins.
Main Methods:
- Varicella-Zoster-Virus was labeled with [35S]methionine and purified using sucrose density gradient centrifugation.
- High-resolution polyacrylamide gel electrophoresis and fluorography were employed for polypeptide analysis.
- Immunoprecipitation with human antiserum was used to identify viral proteins.
Main Results:
- A polypeptide pattern of at least 31 distinct proteins was identified in purified VZV.
- Estimated molecular weights of VZV proteins ranged from 18,000 to 240,000 daltons.
- Immunoprecipitation assays indicated the presence of at least 14 VZV proteins.
Conclusions:
- The study provides a detailed profile of the Varicella-Zoster-Virus proteome.
- This characterization contributes to a better understanding of VZV structure and function.
- The identified proteins serve as potential targets for future VZV research and therapeutic development.